ARC TALKS Webinar: Clinical Trial Updates for the ATTR Community

In this ARC TALKS webinar, ARC's own Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on ATTR amyloidosis. Kristen will also explored the direction future research.

The webinar concluded with a Q and A session.

This webinar was original presented on June 20, 2024.

0:00 — Intro
4:19 — What is a Clinical Trial?
8:06 — Should I Participate in a Trial?
10:13 — ATTR Amyloidosis Clinical Trials
14:00 — Clinical Trials Currently Recruiting
15:29 — MAGNITUDE (NTLA-2001; CRISPR Gene Editing)
21:36 — DepleTTR-CM (ALXN2220; Amyloid Depleter)
24:35 — Ongoing Clinical Trials
24:57 — ATTRibute-CM (Acoramidis; TTR Stabilizer)
26:16 — HELIOS-B (Vutrisiran; Gene Silencer)
27:25 — CARDIO-TTRansform (Eplontersen; Gene Silencer)
28:38 — Coramitug (NNC6019-0001; Anti-Amyloid Fibril)
29:39 — AT-02 (Pan-Amyloid Anti-Fibril)
31:17 — Planned Future Trials
33:14 — Other Clinical Trials
37:25 — How to Find Clinical Trials
42:00 — Q&A Session
42:33 — What is the upcoming study for hereditary ATTR carriers?
43:12 — What is a “knockdown” TTR drug?
45:09 — Does race have an impact on treatment?
46:24 — Are there studies looking at early diagnosis/natural progression of ATTR?
48:35 — How can people outside of the US participate in studies and trials?
49:44 — Are there clinical trials looking to prevent heart involvement?